Literature DB >> 32099908

Oral swab testing by Xpert® MTB/RIF Ultra for mass tuberculosis screening in prisons.

Fabiano Lima1, Andrea S Santos2, Roberto D Oliveira1, Carla C R Silva2, Crhistinne C M Gonçalves1, Jason R Andrews3, Julio Croda1,4.   

Abstract

Diagnosis of pulmonary tuberculosis is usually achieved by testing sputum for presence of Mycobacterium tuberculosis by microscopy, culture or nucleic acid amplification tests. However, many individuals are unable to produce sputum, particularly early in the course of illness. Studies have reported that oral swabs, assayed by nucleic acid amplification tests, may be a suitable substitute or complement to sputum testing. To determine whether this method could be useful of case finding, in which bacillary load is often lower, we evaluated it in the setting of a mass tuberculosis screening study in prison inmates in Brazil. For this sub-study, we enrolled 128 individuals with pulmonary tuberculosis confirmed by sputum Xpert testing, and 128 controls who tested negative by sputum culture and Xpert. We collected two oral swabs by participant, prior to starting treatment. Swabs were collected from the tongue by brushing along the surface for 10 times. The sensitivity of a single oral swab was 43% (N = 55/128; 95% CI: 34-52%). Using two consecutive oral swabs the sensitivity increased to 51% (N = 66/128; 95% CI: 43-60%). The specificity was 100% (128/128). In participants with high mycobaterial load in the sputum, the combined sensitivity was 90% (N = 9/10). In the participants with medium mycobaterial load in the sputum, the combined sensitivity was 79% (N = 23/29). In the participants with low or very low mycobaterial load in the sputum, the combined sensitivity was 38% (N = 34/89). Our data suggest that oral swab sampling, assayed by Xpert, has comparable sensitivity to sputum in participants with high and medium mycobacterial load in the sputum. However, 70% (89/128) of individuals identified through our mass screening study (Carbone et al.) had detection number low or very low in their sputum. In this population, oral swab testing may not have sufficient sensitivity as currently performed. Further studies are needed to identify alternative non-sputum sampling strategies in this population.
© 2020 The Authors.

Entities:  

Keywords:  Oral swab; Prison; Screening; Tuberculosis; Xpert® MTB/RIF Ultra

Year:  2020        PMID: 32099908      PMCID: PMC7031315          DOI: 10.1016/j.jctube.2020.100148

Source DB:  PubMed          Journal:  J Clin Tuberc Other Mycobact Dis        ISSN: 2405-5794


Diagnosis of pulmonary tuberculosis is usually achieved by testing sputum for presence of Mycobacterium tuberculosis by microscopy, culture or nucleic acid amplification tests. However, many individuals are unable to produce sputum, particularly early in the course of illness. In our studies[1] of mass screening among inmates in Brazil, we have high prevalence of undiagnosed active tuberculosis; however, two-thirds of individuals are unable to produce sputum for testing. The World Health Organization has identified non-sputum based diagnostic tests as a key priority for diagnostic development. Studies have reported that oral swabs, assayed by nucleic acid amplification tests, may be a suitable substitute or complement to sputum testing [2,3,4]. One recent study found that two orals swabs had equivalent sensitivity as a sputum sample [5]. To determine whether this method could be useful in case finding, in which bacillary load is often lower, we evaluated it in the setting of a mass tuberculosis screening study in prison inmates in Brazil. This study was approved by Federal University of Grande Dourados of Institutional Review Board. Between 2017 and 2018, inmates from the three prisons in Brazil were screened for tuberculosis by symptom assessment, chest radiography, sputum testing by Xpert® MTB/RIF 4th generation and culture. This sub-study was performed between April and September of 2018 we enrolled 128 individuals with pulmonary tuberculosis confirmed by sputum Xpert testing, and 128 controls who tested negative by sputum culture and Xpert. Two oral swabs were collected by participants. The first swab was collected prior to starting treatment and the second was collected the next day. Swabs were collected from the tongue by brushing along the surface for 10 times. Swabs were stored in ependorf with 700 uL sterile lysis buffer for 24 h at room temperature, and analyzed on Xpert Ultra assay. The second specimen was stored in a −80°C freezer for up to 12 weeks and then retested. Threshold-cycle (Ct) of multiple probes targeting the rpoB gene was used to estimate mycobaterial load. From that, the Xpert MTB/RIF Ultra quantifies the mycobacterial load as high, medium, low, and very low. The sensitivity of a single oral swab was 43% (N = 55/128; 95% CI: 34–52%). Using two consecutive oral swabs the sensitivity increased to 51% (N = 66/128; 95% CI: 43–60%). The specificity was 100% (128/128). In participants with high mycobaterial load in the sputum, the combined sensitivity was 90% (N = 9/10). In the participants with medium mycobaterial load in the sputum, the combined sensitivity was 79% (N = 23/29). In the participants with low or very low mycobaterial load in the sputum, the combined sensitivity was 38% (N = 34/89) (Table 1).
Table 1

Sensitivity of oral swab testing with Xpert® MTB/RIF Ultra compared with sputum Xpert® MTB/RIF copy number classification.

Sputum Xpert MTB/RIF copy number classificationDetected by one oral swab (%)Detected by two oral swabs (%)Mean number of symptomsa (±SD)
High9/10 (90)9/10 (90)4.1 (±2.7)
Medium22/29 (76)23/29 (79)3.0 (±2.6)
Low16/60 (27)23/60 (38)2.4 (±2.4)
Very Low8/29 (28)11/29 (38)2.6 (±1.9)
All55/128 (43)66/128 (51)2.7 (±2.3)

Tuberculosis symptoms according to World Health Organization guidelines: cough, expectoration, fever, night sweats, weight loss, recent loss of appetite, chest pain, and dyspnea.

Sensitivity of oral swab testing with Xpert® MTB/RIF Ultra compared with sputum Xpert® MTB/RIF copy number classification. Tuberculosis symptoms according to World Health Organization guidelines: cough, expectoration, fever, night sweats, weight loss, recent loss of appetite, chest pain, and dyspnea. Studies suggest that oral swabs have comparable sensitivity to sputum testing by Xpert in individuals diagnosed with tuberculosis [5]. Oral swabs enable sampling in individuals who cannot provide sputum and potentially reduce bioaerosol hazards during collection. However, these studies did not report results stratified by mycobaterial load. Our data suggest that oral swab sampling, assayed by Xpert, as comparable sensitivity to sputum in participants with high and medium mycobacterial load in the sputum. However, 70% (89/128) of individuals identified through our mass screening study [6] had detection number low or very low in their sputum. In this population, oral swab testing may not have sufficient sensitivity as currently performed. Further studies are needed to identify alternative non-sputum sampling strategies in this population.
  5 in total

1.  Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations.

Authors:  Ann Drobnik; Caroline Judd; David Banach; Joseph Egger; Kevin Konty; Eric Rude
Journal:  Am J Public Health       Date:  2011-09-22       Impact factor: 9.308

2.  Fingerprick Versus Oral Swab: Acceptability of Blood-Based Testing Increases If Other STIs Can Be Detected.

Authors:  Ivan Balán; Timothy Frasca; Mobolaji Ibitoye; Curtis Dolezal; Alex Carballo-Diéguez
Journal:  AIDS Behav       Date:  2017-02

3.  Ebola Virus Disease Diagnostics, Sierra Leone: Analysis of Real-time Reverse Transcription-Polymerase Chain Reaction Values for Clinical Blood and Oral Swab Specimens.

Authors:  Bobbie R Erickson; Tara K Sealy; Tim Flietstra; Laura Morgan; Brima Kargbo; Victor E Matt-Lebby; Aridth Gibbons; Ayan K Chakrabarti; James Graziano; Lance Presser; Mike Flint; Brian H Bird; Shelley Brown; John D Klena; Dianna M Blau; Aaron C Brault; Jessica A Belser; Johanna S Salzer; Amy J Schuh; Michael Lo; Marko Zivcec; Rachael A Priestley; Meredith Pyle; Christin Goodman; Scott Bearden; Brian R Amman; Alison Basile; Éric Bergeron; Michael D Bowen; Kimberly A Dodd; Molly M Freeman; Laura K McMullan; Christopher D Paddock; Brandy J Russell; Angela J Sanchez; Jonathan S Towner; David Wang; Galina E Zemtsova; Robyn A Stoddard; Maryann Turnsek; Lisa Wiggleton Guerrero; Shannon L Emery; Janae Stovall; Markus H Kainulainen; Jamie L Perniciaro; Slavica Mijatovic-Rustempasic; Gulchekhra Shakirova; Jörn Winter; Christopher Sexton; Feng Liu; Kimetha Slater; Raydel Anderson; Lauren Andersen; Cheng-Feng Chiang; Wen-Pin Tzeng; Samuel J Crowe; Matthew J Maenner; Christina F Spiropoulou; Stuart T Nichol; Ute Ströher
Journal:  J Infect Dis       Date:  2016-08-31       Impact factor: 5.226

4.  Noninvasive Detection of Tuberculosis by Oral Swab Analysis.

Authors:  Angelique K Luabeya; Rachel C Wood; Mark Hatherill; Gerard A Cangelosi; Justin Shenje; Elizabeth Filander; Cynthia Ontong; Simbarashe Mabwe; Hadn Africa; Felicia K Nguyen; Alaina Olson; Kris M Weigel; Lisa Jones-Engel
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

5.  Impact of mass-screening on tuberculosis incidence in a prospective cohort of Brazilian prisoners.

Authors:  Dayse Sanchez Guimarães Paião; Everton Ferreira Lemos; Andrea da Silva Santos Carbone; Renata Viebrantz Enne Sgarbi; Alexandre Laranjeira Junior; Fellipe Matos da Silva; Letícia Marques Brandão; Luciana Squarizi Dos Santos; Vaneli Silva Martins; Simone Simionatto; Ana Rita Coimbra Motta-Castro; Maurício Antônio Pompílio; Juliana Urrego; Albert Icksang Ko; Jason Randolph Andrews; Julio Croda
Journal:  BMC Infect Dis       Date:  2016-10-03       Impact factor: 3.090

  5 in total
  10 in total

1.  Evaluating the efficacy of stool sample on Xpert MTB/RIF Ultra and its comparison with other sample types by meta-analysis for TB diagnostics.

Authors:  Vishal Sharma; Anoop Singh; Mohita Gaur; Deepti Rawat; Anjali Yadav; Chanchal Kumar; Mandira Varma-Basil; Sheelu Lohiya; Vishal Khanna; Ashwani Khanna; Anil Chaudhry; Yogendra Singh; Richa Misra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-05-04       Impact factor: 3.267

2.  Accuracy of Tongue Swab Testing Using Xpert MTB-RIF Ultra for Tuberculosis Diagnosis.

Authors:  A Andama; G R Whitman; R Crowder; T F Reza; D Jaganath; J Mulondo; T K Nalugwa; F C Semitala; W Worodria; C Cook; R C Wood; K M Weigel; A M Olson; J Lohmiller Shaw; M Kato-Maeda; C M Denkinger; P Nahid; G A Cangelosi; A Cattamanchi
Journal:  J Clin Microbiol       Date:  2022-06-27       Impact factor: 11.677

3.  Gene-Based Diagnosis of Tuberculosis from Oral Swabs with a New Generation Pathogen Enrichment Technique.

Authors:  Young Ae Kang; Bonhan Koo; Yong Shin; Sei Won Lee; Ock-Hwa Kim; Joung Ha Park; Ho Cheol Kim; Hyo Joo Lee; Myoung Gyu Kim; Youngwon Jang; Na Hyun Kim; Yong Seo Koo; Sung-Han Kim
Journal:  Microbiol Spectr       Date:  2022-05-19

4.  Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.

Authors:  Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne
Journal:  Cochrane Database Syst Rev       Date:  2021-03-23

5.  Diagnostic Yield of Oral Swab Testing by TB-LAMP for Diagnosis of Pulmonary Tuberculosis.

Authors:  Yanhua Song; Yifeng Ma; Rongmei Liu; Yuanyuan Shang; Liping Ma; Fengmin Huo; Yunxu Li; Wei Shu; Yufeng Wang; Mengqiu Gao; Yu Pang
Journal:  Infect Drug Resist       Date:  2021-01-12       Impact factor: 4.003

6.  Diagnostic performance of oral swabs for non-sputum based TB diagnosis in a TB/HIV endemic setting.

Authors:  Sylvia M LaCourse; Evans Seko; Rachel Wood; Wilfred Bundi; Gregory S Ouma; Janet Agaya; Barbra A Richardson; Grace John-Stewart; Steve Wandiga; Gerard A Cangelosi
Journal:  PLoS One       Date:  2022-01-13       Impact factor: 3.240

Review 7.  A systematic review of potential screening biomarkers for active TB disease.

Authors:  James H Wykowski; Chris Phillips; Thao Ngo; Paul K Drain
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-11-05

Review 8.  Diagnosing Tuberculosis: What Do New Technologies Allow Us to (Not) Do?

Authors:  Shima M Abdulgader; Anna O Okunola; Gcobisa Ndlangalavu; Byron W P Reeve; Brian W Allwood; Coenraad F N Koegelenberg; Rob M Warren; Grant Theron
Journal:  Respiration       Date:  2022-06-27       Impact factor: 3.966

9.  The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal.

Authors:  Emily A Kendall; Sourya Shrestha; David W Dowdy
Journal:  Am J Respir Crit Care Med       Date:  2021-01-15       Impact factor: 21.405

Review 10.  Reimagining the status quo: How close are we to rapid sputum-free tuberculosis diagnostics for all?

Authors:  Ruvandhi R Nathavitharana; Alberto L Garcia-Basteiro; Morten Ruhwald; Frank Cobelens; Grant Theron
Journal:  EBioMedicine       Date:  2022-03-23       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.